Background: Sarcoidosis is a highly heterogeneous disease, leading to differences in clinical practices across countries. This study aimed to identify similarities and differences in diagnostic, therapeutic, and follow-up practices for sarcoidosis across European coun-tries. Methods: Within the Joint Action on REspiratory Diseases (JARED) project, we conducted a multinational, cross-sectional study using a key informant expert survey. The structured survey comprised 48 questions on adult sarcoidosis diagnostics and management. Rep-resentatives of all 15 JARED project countries completed the electronic survey. Results: Sarcoidosis and/or interstitial lung disease centres are present in 12 countries, but only 7 have national guidelines for diagnosis and treatment. In most countries, bron-choscopy with bronchoalveolar lavage and endobronchial ultrasound-guided lymph node biopsy are performed. The use of bronchoscopic lung biopsies, particularly cryo-biopsies, varies considerably. To assess the extent and activity of the disease, almost all countries perform extended pulmonary function testing, but there are variations in the use of hypercalcaemia and hypercalciuria tests. Positron emission tomography is used routinely only in 4 countries. Around half of the patients are treated with corticosteroids. In most cases, treatment is initiated when an organ other than the lungs is affected or when severe pulmonary function impairment is present. The follow-up intervals range from 1 to 12 months. The monitoring strategies vary based on the radiological stage of sarcoidosis or the severity of the disease. Conclusions: Our survey highlights substantial variation in sarcoidosis management across Europe, underscoring the need for updated, evidence-based recommendations on diagnostic strategies, treatment initiation and duration, and long-term follow-up.